Pavlick, Anna C;
Ariyan, Charlotte E;
Buchbinder, Elizabeth I;
Davar, Diwakar;
Gibney, Geoffrey T;
Hamid, Omid;
Hieken, Tina J;
Izar, Benjamin;
Johnson, Douglas B;
Kulkarni, Rajan P;
Luke, Jason J;
Mitchell, Tara C;
Mooradian, Meghan J;
Rubin, Krista M;
Salama, April K. S;
Shirai, Keisuke;
Taube, Janis M;
Tawbi, Hussein A;
Tolley, J Keith;
Valdueza, Caressa;
Weiss, Sarah A;
Wong, Michael K;
Sullivan, Ryan J.
Since the first approval for immune checkpoint inhibitors
(ICIs) for the treatment of cutaneous melanoma more than
a decade ago, immunotherapy has completely transformed
the treatment landscape of this chemotherapy-resistant
disease. Combination regimens including ICIs directed
against programmed cell de...
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered...
